跳至主要内容
临床试验/CTRI/2021/09/036500
CTRI/2021/09/036500
已完成
未知

A PROSPECTIVE STUDY TO COMPARE TUMOR RESPONSE AND TOXICITIES IN UNRESECTABLE NON SMALL CELL LUNG CANCERS TREATED BY CONCURRENT CHEMO RADIOTHERAPY USING TWO CHEMOTHERAPY REGIMENS SUCH AS CISPLATIN & ETOPOSIDE VS CARBOPLATIN & PACLITAXEL.

svims tirupati0 个研究点目标入组 34 人待定

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
发起方
svims tirupati
入组人数
34
状态
已完成
最后更新
3年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
2022年12月16日
最后更新
3年前
研究类型
Interventional

研究者

发起方
svims tirupati

入排标准

入选标准

  • Histopathologically proven non small cell lung cancer patients.
  • 2\.Unresectable lung cancers according to NCCN /BTS guidelines VI
  • 3\.Patients with adequate hematologic parameters hemoglobin HB \>\=10g/dl, total white blood cell (WBC) \>\= 4000/mm3 and platelets \>\= 100,000/mm3 )and renal function \>\= 60ml/min.
  • 4\. Patients with Eastern Cooperative Oncology Group (ECOG) performance status (0\-2\)
  • 5\.Patients having age 18\-65 years.
  • 6\.Patients who are willing to give an approved informed consent

排除标准

  • Patients who already treated with surgery ,radiation therapy or chemotherapy for ca lung.
  • Patients with known distant metastases \& malignant pleural effusion.
  • Patients with (ECOG) performance status 3\- 4
  • Clinically significant cardiovascular comorbidities.
  • 5\.Pregnant women and lactating mothers

结局指标

主要结局

未指定

相似试验